|
Patent landscape, scope, and claims summary: |
Analysis of United States Patent 7,422,739: Theophylline Formulations
This analysis examines United States Patent 7,422,739, titled "Theophylline Formulations," issued on September 9, 2008, to Depomed, Inc. The patent claims methods and compositions for controlled release of theophylline. Theophylline is a bronchodilator used in treating respiratory diseases. The patent's core innovation lies in a sustained-release formulation designed to maintain therapeutic drug levels with reduced dosing frequency and potentially fewer side effects compared to immediate-release forms.
What Does United States Patent 7,422,739 Claim?
Patent 7,422,739 claims a pharmaceutical composition comprising theophylline and a water-swellable polymer matrix. The matrix is formulated to release theophylline at a controlled rate. The claims define specific parameters for this controlled release, including dissolution profiles and the use of particular polymeric materials.
The key claims of the patent include:
- Claim 1: A pharmaceutical composition for oral administration comprising theophylline and a therapeutically effective amount of a water-swellable polymer in an amount sufficient to provide a sustained release of theophylline. The polymer has a gel strength of at least 1 gram.
- Claim 10: A method of treating a patient suffering from a bronchodilator-responsive disease comprising administering to the patient a pharmaceutical composition of claim 1, wherein the composition is administered once or twice daily.
- Claim 22: A controlled release pharmaceutical formulation comprising theophylline, a water-swellable polymer, and a pharmaceutically acceptable diluent, wherein the formulation is a compressed tablet and wherein the water-swellable polymer is present in a sufficient amount to control the release of theophylline such that the release rate in vitro is described by the equation: $Q = kt^{0.45}$, where Q is the cumulative amount of theophylline released at time t, and k is a constant.
The patent specifies various types of water-swellable polymers, including but not limited to hydroxypropyl methylcellulose (HPMC) and polycarbophil. It also details dissolution testing parameters, such as using a USP apparatus 1 at 100 rpm in a phosphate buffer at pH 6.8. The target release profile aims for a specific percentage of theophylline released over defined time periods, for example, between 20% and 60% release at 4 hours, and greater than 80% release by 12 hours.
What is the Underlying Technology and Its Significance?
The technological foundation of Patent 7,422,739 is controlled-release drug delivery. Traditional immediate-release formulations of theophylline require frequent dosing (e.g., every 6-8 hours) to maintain therapeutic concentrations. This leads to fluctuations in blood levels, potentially causing side effects at peak concentrations and sub-therapeutic levels between doses.
The innovation in this patent is the use of a specific polymer matrix to create a sustained-release profile. When the tablet contacts gastrointestinal fluids, the water-swellable polymer absorbs water, swells, and forms a gel layer. The theophylline then diffuses out of this gel matrix at a controlled rate. This sustained release aims to:
- Reduce Dosing Frequency: Allowing for once or twice daily administration, improving patient compliance.
- Minimize Peak-Trough Fluctuations: Leading to more stable plasma concentrations and potentially fewer dose-related side effects.
- Maintain Therapeutic Efficacy: Ensuring the drug remains at effective levels for longer periods.
The specific focus on a water-swellable polymer and the defined release kinetics (e.g., the $t^{0.45}$ exponent in Claim 22, indicative of anomalous diffusion or a combination of diffusion and erosion) differentiate this formulation from earlier sustained-release technologies. The gel strength requirement also adds a specific physical characteristic to the polymer matrix.
What is the Patent Landscape for Theophylline Formulations?
The patent landscape for theophylline formulations is established, with prior art addressing immediate-release and various controlled-release technologies. However, Patent 7,422,739 carves out a specific niche by defining a particular type of water-swellable polymer matrix and associated release kinetics.
Key aspects of the patent landscape include:
- Existing Theophylline Drugs: Several theophylline products have been on the market for decades, including immediate-release and older sustained-release formulations (e.g., Theo-Dur, Uniphyl). These prior art products establish the therapeutic utility of theophylline.
- General Controlled-Release Technologies: A vast body of patents exists for general controlled-release technologies, utilizing various polymer systems (e.g., hydrophilic matrices, osmotic pumps, enteric coatings, lipid-based systems). Patent 7,422,739's claims are specific to a hydrophilic matrix system with particular characteristics.
- Polymer-Based Drug Delivery: Patents covering the use of specific polymers like HPMC and polycarbophil in drug formulations are numerous. The novelty of 7,422,739 rests on its application of these polymers in a specific matrix configuration for theophylline and the defined release profile.
- Bioequivalence and Generics: The expiration of patents for older theophylline formulations has led to a competitive generic market. New formulations, like those claimed in 7,422,739, aim to offer improved profiles that can command market share or be licensed to established pharmaceutical companies.
A detailed patent search would reveal the extent of prior art related to theophylline delivered via hydrophilic matrices and specific release exponents. However, the claims' specificity regarding polymer properties (gel strength) and the release equation are crucial for defining the patent's scope and potential infringement.
What are the Key Dates and Status of the Patent?
United States Patent 7,422,739 has the following key dates:
- Application Filing Date: May 31, 2005
- Publication Date: December 1, 2005 (as US 2005/0266040 A1)
- Issue Date: September 9, 2008
- Expiration Date: May 31, 2025 (based on a standard 20-year patent term from the filing date, assuming no extensions or adjustments)
As of the current date, the patent is in force. Its expiration date in May 2025 signifies a limited remaining exclusivity period for any products relying solely on this patent.
What are the Commercial Implications and Market Potential?
The commercial implications of Patent 7,422,739 are tied to its potential to create differentiated theophylline products. For Depomed, Inc., the patent would have supported the development and commercialization of a branded sustained-release theophylline product, likely targeting improved patient compliance and reduced adverse events compared to generics.
Key commercial considerations include:
- Branded Product Development: Depomed could have developed a product based on this patent (e.g., as a line extension or a new entity) to compete in the respiratory market. Successful commercialization would depend on demonstrating superior efficacy, safety, or convenience over existing therapies.
- Licensing Opportunities: Depomed could license the patent rights to larger pharmaceutical companies with established respiratory franchises, enabling wider market reach and potentially generating royalty revenue.
- Generic Entry Post-Expiration: Following the patent's expiration in May 2025, generic manufacturers could seek to produce their own versions of the claimed formulation, provided they do not infringe on other active patents or regulatory exclusivities.
- Market Size: The market for bronchodilators remains significant due to the prevalence of COPD and asthma. While theophylline is an older drug class, a well-formulated, convenient product could capture a segment of this market, particularly if it offers demonstrable clinical advantages.
- Competition: The primary competition comes from other bronchodilators, including short-acting and long-acting beta-agonists (SABAs/LABAs), long-acting muscarinic antagonists (LAMAs), and combination therapies. Theophylline's position has shifted towards a third-line or adjunctive therapy for many patients.
The patent's value proposition is the enhanced delivery profile. Demonstrating a clinically meaningful improvement in patient outcomes (e.g., fewer exacerbations, improved quality of life) would be crucial for commercial success against established therapies and generics.
What Are the Potential Challenges and Risks?
The development and commercialization of products based on Patent 7,422,739 face several challenges and risks:
- Clinical Efficacy and Safety: While sustained-release formulations aim to improve safety and efficacy, theophylline itself has a narrow therapeutic index. Careful clinical trials are required to demonstrate that the specific formulation achieves these benefits without compromising safety.
- Regulatory Hurdles: Obtaining FDA approval for a new drug product requires extensive clinical data demonstrating safety and efficacy. Demonstrating bioequivalence to a reference listed drug (if applicable) or establishing a new therapeutic indication are rigorous processes.
- Market Acceptance: Theophylline is an older drug, and newer classes of bronchodilators (e.g., LABAs, LAMAs) are often preferred as first-line treatments for COPD and asthma due to improved safety profiles and efficacy in specific patient populations. Physician and patient adoption of a new theophylline product would depend on clearly demonstrating its value.
- Patent Litigation: While the patent is currently in force, it could face challenges from generic manufacturers seeking to invalidate it or design around its claims.
- Generic Competition Post-Expiration: As noted, the patent's expiration date limits the period of market exclusivity. Companies must maximize market penetration and brand loyalty before generic entry.
- Manufacturing Complexity and Cost: Developing and manufacturing controlled-release formulations can be more complex and costly than immediate-release products, potentially impacting profit margins.
Key Takeaways
- Patent 7,422,739 protects a specific sustained-release formulation of theophylline using a water-swellable polymer matrix. The claims define particular polymer properties (gel strength) and release kinetics.
- The patent aims to improve patient compliance and reduce side effects through once or twice-daily dosing. This addresses limitations of immediate-release theophylline.
- The patent term extends to May 31, 2025. This provides a limited window for market exclusivity.
- Commercial success depends on demonstrating clinical advantages over existing theophylline generics and newer bronchodilator classes. Market adoption will require robust clinical data and physician acceptance.
- The patent landscape for theophylline is crowded, but the specificity of 7,422,739's claims regarding formulation and release profile defines its scope.
Frequently Asked Questions
-
What is the primary therapeutic use for theophylline formulations covered by this patent?
The primary therapeutic use is for bronchodilation in respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD).
-
How does the formulation claimed in Patent 7,422,739 differ from standard immediate-release theophylline?
The claimed formulation utilizes a water-swellable polymer matrix to control the rate of theophylline release over an extended period, allowing for less frequent dosing (once or twice daily) and more stable plasma concentrations, unlike immediate-release forms which require more frequent administration.
-
What is the expiration date of United States Patent 7,422,739?
The patent is scheduled to expire on May 31, 2025.
-
What specific types of polymers are mentioned in the patent for creating the sustained-release matrix?
The patent mentions water-swellable polymers, including but not limited to hydroxypropyl methylcellulose (HPMC) and polycarbophil, in amounts sufficient to provide sustained release and achieve a specific gel strength.
-
Can generic versions of theophylline formulations protected by this patent be marketed before its expiration?
Generic manufacturers can market products that do not infringe on the active claims of Patent 7,422,739. Following the patent's expiration on May 31, 2025, generic versions of the claimed formulation may be introduced, assuming no other patents or regulatory exclusivities are in effect.
Cited Sources
[1] Depomed, Inc. (2008). United States Patent 7,422,739: Theophylline formulations. U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
